---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-278334"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:15:10.033147+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Homology Medicines to merge with Q32 Bio, valuing Q32 at $195M; CEO and CFO terminated

## Summary
- All-stock merger ascribes Q32 equity value of $195M; Homology equity ~$80M; Q32 stockholders to receive Homology common shares.
- Q32 to raise $42M in concurrent financing from accredited investors immediately before close.
- Combined board to have 9 members: 2 from Homology, 7 from Q32 (indicating Q32 control).
- Q32 holders with 74.1% of Q32 capital stock and Homology holders with 18.2% of common stock support deal via support agreements.
- CEO Albert Seymour and CFO W. Bradford Smith terminated; Paul Alloway named President/COO/PEO; Charles Michaud named VP/Controller/Treasurer.

## SEC filing metadata
- accession: 0001193125-23-278334
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/d350392d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-278334
- JSON: https://secwatch.observer/filing/0001193125-23-278334.json
- Plain text: https://secwatch.observer/filing/0001193125-23-278334.txt

## Key facts
- Executive change
  W. Bradford Smith was terminated as Chief Financial and Business Officer and Treasurer at Q32 Bio Inc..
  - Action: terminated
  - Role: Chief Financial and Business Officer and Treasurer
  source text: the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm
- Executive change
  Albert Seymour resigned as Director at Q32 Bio Inc..
  - Action: resigned
  - Role: Director
  source text: Dr. Seymour resigned from the Company’s board of directors, effective as of November 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm
- Executive change
  Albert Seymour was terminated as President and Chief Executive Officer at Q32 Bio Inc..
  - Action: terminated
  - Role: President and Chief Executive Officer
  source text: the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm
- Executive change
  Paul G. Alloway was appointed as President, Chief Operating Officer and Secretary at Q32 Bio Inc..
  - Action: appointed
  - Role: President, Chief Operating Officer and Secretary
  source text: the Board (i) appointed Paul G. Alloway, Ph.D., who currently serves as the Company’s Chief Legal Officer and Secretary, as the Company’s President, Chief Operating Officer and Secretary, and designated Dr. Alloway as the Company’s principal executive officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312523278334/0001193125-23-278334-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.